Comparative Evaluation of Imatinib and Nilotinib in a Streptozotocin-Induced Rat Model of Alzheimer’s Disease : Neuroprotective, Anti-inflammatory, and Cognitive Outcomes
Open Access
- 1 May 2026
- journal article
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 421-432
Abstract
Objective : Alzheimer’s disease is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) peptide aggregation, representing a major therapeutic target. Emerging evidence suggests certain chemotherapeutic agents may attenuate Aβ pathology.Methods : This study investigated the effects of imatinib, a tyrosine kinase inhibitor with limited blood-brain barrier (BBB) penetration, and nilotinib, with enhanced BBB permeability, in an intracerebroventricular streptozotocin (ICV-STZ) rat model of Alzheimer’s disease. Outcomes included behavioral assessments (learning latency), hippocampal CA1 and CA3 neuronal counts, and brain concentrations of tumor necrosis factor (TNF)-α, nuclear factor kappa B (NF-κB), brain-derived neurotrophic factor (BDNF), and neuregulin-1 (NRG-1).Results : ICV-STZ administration significantly elevated TNF-α and NF-κB levels and reduced BDNF and NRG-1 expression. Both imatinib and nilotinib mitigated these alterations, with imatinib demonstrating greater efficacy despite its limited BBB permeability. Imatinib and nilotinib reduced TNF-α and NF-κB levels, increased BDNF and NRG-1 expression, and significantly improved cognitive performance, with latency periods extending from 69.8 seconds in the disease model to 193.5 and 183.1 seconds, respectively.Conclusion : Imatinib and nilotinib ameliorated neuroinflammation, restored neurotrophic support, and improved cognitive deficits in a preclinical Alzheimer’s disease model. These findings highlight the therapeutic potential of tyrosine kinase inhibitors, warranting further translational research in human studies.Keywords
This publication has 66 references indexed in Scilit:
- Aqueous extract of Spirulina exerts neuroprotection in an experimental model of Alzheimer sporadic disease in mice induced by StreptozotocinMetabolic Brain Disease, 2024
- Canagliflozin Mitigated Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer’s Disease in Mice: Role of AMPK/SIRT-1 Signaling Pathway in Modulating NeuroinflammationJournal of Neuroimmune Pharmacology, 2024
- Neuroprotective Effect of Chlorogenic Acid in an Animal Model of Sporadic Alzheimer's Disease Induced by StreptozotocinMolecular Neurobiology, 2024
- Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's DiseaseAnnals of Neurology, 2020
- In silico identification of natural product inhibitors for γ‐secretase activating protein, a therapeutic target for Alzheimer's diseaseJournal of Cellular Biochemistry, 2018
- Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearanceJournal of Molecular Medicine, 2013
- Activity dynamics and behavioral correlates of CA3 and CA1 hippocampal pyramidal neuronsHippocampus, 2012
- Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: Implications for Alzheimer's diseaseJournal of Neuroscience Research, 2011
- Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairmentAnnals of Neurology, 2002
- Alzheimer's diseaseJournal of the Neurological Sciences, 1982